Genetically Defined Attenuated Living Vaccine for Francisella

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$588,104.00
Award Year:
2007
Program:
STTR
Phase:
Phase I
Contract:
1R41AI072906-01A1
Award Id:
85296
Agency Tracking Number:
AI072906
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
VIROGENOMICS, INC., 9020 SW WASHINGTON SQUARE RD, TIGARD, OR, 97223
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
045283590
Principal Investigator:
FRED HEFFRON
(503) 494-6738
HEFFRONF@OHSU.EDU
Business Contact:
GILBERT MILLER
() -
gil.miller@virogenomics.com
Research Institution:
OREGON HEALTH AND SCIENCE UNIVERSITY

OREGON HEALTH AND SCIENCE UNIVERSITY
3181 SW Sam Jackson Pk Rd
PORTLAND, OR, 97239-3098

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Tularemia is the severe and sometimes fatal disease caused by infection with Francisella tularensis. These bacteria are some of the most virulent pathogens known, requiring inoculation or inhalation with as few as 10 or ganisms to cause disease. Infections can be acquired in a variety of ways: bites from an arthropod vector, skin lesions, ingestion of contaminated food or water, or inhalation of aerosolized particles. Its low infectious dose and relative ease of airborne transmission led to the development of F. tularensis as a biological weapon by several national weapons programs. Because it presents a serious threat to national security, the Centers for Disease Control (CDC) classify F. tularensis as a category A select agent. Despite these criteria, there is no approved tularemia vaccine. The goal of the research described herein is to construct a rationally attenuated living vaccine against tularemia. We will build upon our previous discovery of genes required for viru lence in F. tularemia, mutant derivatives of which provide protection against wild-type challenge in mice. These genes will be deleted, individually and in combinations, in the most virulent subspecies of the organism, resulting in attenuated, non-revertin g, defined strains that do not specify antibiotic resistance. After confirming that these strains protect mice against wild-type challenge, we propose to test the vaccines in a non-human primate model, a necessary step to achieving FDA approval. Tularemia is the severe and sometimes fatal disease caused by infection with Francisella tularensis. Its low infectious dose and relative ease of airborne transmission led to the development of F. tularensis as a biological weapon by several national weapons program s. As there is no approved tularemia vaccine, we seek to develop a live attenuated tularemia vaccine.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government